The phakomatoses: Recent advances in genetics

Canadian Journal of Ophthalmology

Volumn 32, Issue 1, 1997, Pages 4-11

  MacDonald, Ian M ^a   Bech Hansen, N Torben ^b   Britton Jr , William A ^c   Green, Jane ^d   Paterson, Malcolm ^e   Stone, James ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e CROSS CANCER INSTITUTE   (Canada)

Author keywords

Ataxia telangiectasia; Genetics; Neurofibromatosis; Phakomatosis; Sturge Weber syndrome; Tuberous sclerosis,; Von Hippel Lindau disease; Wyburn Mason syndrome

Indexed keywords

ATAXIA TELANGIECTASIA; GENETIC COUNSELING; HUMAN; NEUROFIBROMATOSIS; PHAKOMATOSIS; REVIEW; STURGE WEBER SYNDROME; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE; WYBURN MASON SYNDROME;

EID: 0030938302     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Sujansky E, Conradi S. Outcome of Sturge-Weber syndrome in 52 adults. Am J Med Genet 1995;57:35-45.
2. Bebin EM, Gomez MR. Prognosis in Sturge-Weber disease: comparison of unihemispheric and bihemispheric involvement. J Child Neurol 1988;3:181-4.
3. Truhan AP, Filipek PA. Magnetic resonance imaging. Its role in the neuroradiologic evaluation of neurofibromatosis, tuberous sclerosis, and Sturge-Weber syndrome. Arch Dematol 1993;129:219-26.
4. Tripathi BJ, Tripathi RC, Cibis GW. Sturge-Weber syndrome. Encephalotrigeminal angiomatosis. In: Gold DH, Weingeist TA, editors. The eye in systemic disease. Philadelphia: J B Lippincott, 1990:443-7.
5. Sujansky E, Conradi S. Sturge-Weber syndrome: age of onset of seizures and glaucoma and the prognosis for affected children. J Child Neurol 1995;10:49-58.
6. Cibis GW, Tripathi RC, Tripathi BJ. Glaucoma in Sturge-Weber syndrome. Ophthalmology 1984;91:1061-71.
7. Debicka A, Adamczak P. Przyoadel dziedziczenia zespolu Sturge'a-Webera. Klin Oczna 1979;81:541-2.
8. Enjolras O, Riche MC, Merland JJ. Facial port-wine stains and Sturge-Weber syndrome. Pediatrics 1985;76:48-51.
9. Barker D, Wright E, Nguyent K, et al. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 1987;49:589-94.
10. Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 1986;322:644-7.
11. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI. NIH Conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis): an update. Ann Intern Med 1990;113:39-52.
12. Huson S, Jones D, Beck L. Ophthalmic manifestations of neurofibromatosis. Br J Ophthalmol 1987;71:235-8.
13. Cohen MM Jr. Further diagnostic thoughts about the Elephant Man. Am J Med Genet 1988;29:777-82.
14. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990;249:181-6.
15. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990;63:851-9.
16. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990;63:843-9.
17. Xu G, O'Connell P, Viskochil D, Cawthon R, Robertson M, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990;62:599-608.
18. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994;8:1019-29.
19. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nature Genet 1993;3:122-6.
20. Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992;356:713-5.
21. ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992;69:265-73.
22. Cho BC, Shaughnessy JD Jr, Largaespada DA, Bedigian HG, Buchberg AM, et al. Frequent disruption of the NF1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas. J Virol 1995;69: 7138-46.
23. Marchuk DA, Saulino AM, Favakkol R, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 1991;11: 931-40.
24. Gahu A, Lau N, Huvar I, Gutmann D, Provias J, et al. RAS-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 1996;12:507-13.
25. Sedgwick RP, Boder E. Ataxia-telangiectasia. In: de Jong JMB, editor. Handbook of clinical neurology. VoL 16: Hereditary neuropathies and spinocellular atrophies. Amsterdam: Elsevier, 1991;347-423.
26. Gatti RA, Boder E, Vinters HV, Sparkes RS, Norman A, et al. Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine 1991;70:99-117.
27. Boder E. Ataxia-telangiectasia. In: Gomez MR, editor. Neurocutaneous diseases: a practical approach. London: Butterworths, 1987;95-117.
28. Easton DF. Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994;66:S177-82.
29. Paterson MC. Breast cancer-predisposing genes: their discovery marks a turning point in deciphering a complex disease. Ann Saudi Med 1996;16:243-8.
30. Byrd PJ, McConville CM, Cooper P, Parkhill J, Stankovic T, et al. Mutations revealed by sequencing the 5' half of the gene for ataxia-telangiectasia. Hum Mol Genet 1996;5: 145-9.
31. Swift M, Morrell D, Massey RBM, et al. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991;325:1831-6.
32. McKinnon PJ. Ataxia-telangiectasia: an inherited disorder of ionizing-radiation sensitivity in man. Hum Genet 1987; 75:197-208.
33. Paterson MC, Smith PJ. Ataxia-telangiectasia - an inherited human disorder involving hypersensitivity to ionizing radiation and related DNA-damaging chemicals. Annu Rev Genet 1979;13:291-318.
34. Shiloh Y. Ataxia-telangiectasia: closer to unravelling the mystery. Eur J Hum Genet 1995;3:116-38.
35. Lavin MF. Biochemical defects in ataxia-telangiectasia. In: Gatti RA, Painter RB, editors. Ataxia-telangiectasia. Vol H77 of NATO ASI series. Berlin: Springer-Verlag, 1993:235-55.
36. Beamish H, Khanna KK, Lavin MF. Ionizing radiation and cell cycle progression in ataxia-telangiectasia. Radiat Res 1994;138(suppl):S130-3.
37. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
38. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53.
39. Gatti RA, Berkel I, Boder E, et al. Localisation of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 1988;336:577-80.
40. Zakian VA. ATM-related genes: What do they tell us about functions of the human gene? Cell 1995;82:685-7.
41. Lamiell JM, Salazar FG, Hsia YE. Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine 1989;68:1-29.
42. Maher ER, Yates JRW, Harris R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-63.
43. Green JS. Development, implementation and evaluation of clinical and genetic screening programs for hereditary tumour syndromes [dissertation]. St John's (NF): Memorial University, 1996.
44. Maher ER, Webster AR, Moore AT. Clinical features and molecular genetics of von Hippel-Lindau disease. Ophthalmic Pediatr Genet 1995;16:79-84.
45. Lowden BA, Harris GS. Pheochromocytoma and von Hippel-Lindau's disease. Can J Ophthalmol 1976;11: 282-9.
46. Palena PV, Augsburger JJ. Phakomatoses. In: Tasman W, editor. Duane's clinical ophthalmology. Vol 3, chapt 34. Philadelphia: J B Lippincott, 1995:1-12.
47. Ridley M, Green J, Johnson G. Retinal angiomatosis: the ocular manifestations of von Hippel-Lindau disease. Can J Ophthalmol 1986;21:276-83.
48. Moore AT, Maher ER, Rosen P, et al. Ophthalmological screening for von Hippel-Lindau disease. Eye 1991;5: 723-8.
49. Seizinger BR, Rouleau GA, Ozelius LF, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332: 268-9.
50. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
51. Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-8.
52. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
53. Glenn GM, Linehan WM, Hosoe S, et al. Screening for von Hippel-Lindau disease by DNA polymorphism analysis. JAMA 1992;267:1226-31.
54. Maher ER, Bentley E, Payne SJ, et al. Presymptomatic diagnosis of von Hippel-Lindau disease with flanking DNA markers. J Med Genet l992;29:902-5.
55. Gomez MR, editor. Tuberous sclerosis. 2nd ed. New York: Raven Press, 1988:9-19.
56. Asdourian GK, Lewis RA. The phakomatoses. In: Peyman GA, Sanders DR, Goldberg MF, editors. Principles and practice of ophthalmology. Philadelphia: W B Saunders Company, 1980:1186-1204.
57. Garrick R, Gomez MR, Houser OW. Demyelination of the brain in tuberous sclerosis: computed tomography evidence. Mayo Clin Proc 1979;54:685-9.
58. Roach ES, Smith M, Juttenlocher P, Bhat M, Alcorn D, et al. Report of the diagnostic criteria committee of the National Tuberous Sclerosis Association. J Child Neurol 1992;7:221-4.
59. Robertson DM. Ophthalmic findings. In: Gomez MR, editor. Tuberous sclerosis. 2nd ed. New York: Raven Press, 1988:89-109.
60. Zimmer-Galler IE, Robertson DM. Long-term observation of retinal lesions in tuberous sclerosis. Am J Ophthalmol 1995;119:318-24.
61. Sampson JR, Janssen JAJ, Sandkuijl LA, and Tuberous Sclerosis Collaborative Group. Linkage investigation of three putative tuberous sclerosis determining loci on chromosome 9q, 11q and 12q. J Med Genet 1992;29: 861-6.
62. Povey S, Burley MW, Attwood J, et al. Two loci for tuberous sclerosis: one on 9q34 and one on 16q13. Ann Hum Genet 1994;58:107-24.
63. Kandt RS, Haines JL, Smith M, Northrup H, Gardner RJM, et al. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nature Genet 1992;2:37-41.
64. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-15.
65. Carbonara C, Longa L, Grosso E, Borrone C, Garrè MG, et al. 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene. Hum Mol Genet 1994;3:1829-32.
66. Green AJ, Sepp T, Yates JRW. Clonality of tuberous sclerosis hamartomas shown by non-random X chromosome inactivation. Hum Genet 1996;97:240-3.
67. Wienecke R, König A, DeClue JE. Identification of tuberin, the tuberous sclerosis-2 product. J Biol Chem 1995;270:16409-14.
68. Weiderholt WC, Gomez MR, Kurland LT. Incidence and prevalence of tuberous sclerosis in Rochester, Minnesota, 1950 through 1982. Neurology 1985;35:600-3.
69. Osborne P, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci 1991;615:125-7.
70. Kumar A, Kandt RS, Wolpert C, Roses AD, Pericak-Vance MA, et al. Mutation analysis of the TSC2 gene in an African-American family. Hum Mol Genet 1995;4: 2295-8.
71. Kumar A, Wolpert C, Kandt RS, Segal J, Pufky J, et al. A de novo frame-shift mutation in the tuberin gene. Hum Mol Genet 1995;4:1471-2.
72. Vrtel R, Verhoef S, Bouman K, Maheshwar MM, Nellist M, et al. Identification of a nonsense mutation at the 5' end of the TSC2 gene in a family with a presumptive diagnosis of tuberous sclerosis complex. J Med Genet 1996;33: 47-51.
73. Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease: a contiguous gene syndrome. Nature Genet 1994;8:328-32.
74. Wilson PJ, Ramesh V, Kristiansen A, Bove C, Jozwiak S, et al. Novel mutations detected in the TSC2 gene from both sporadic and familial TSC patients. Hum Mol Genet 1996;5:249-56.
75. Sampson JR, Scahill SJ, Stephenson JBP, Mann L, Connor JM. Genetic aspects of tuberous sclerosis in the west of Scotland. J Med Genet 1989;26:28-31.
76. Bonnet P, Dechaume J, Blanc E. L'anévrysme cirsoïde de la rétine (anévrysme racémeux). Ses relations avec l'anévrysme cirsoïde de la face et avec l'anévrysme cirsoïde du cerveau. J Med Lyon 1937;18:165-78.
77. Wyburn-Mason R. Arteriovenous aneurysm of midbrain and retina, facial nerve and mental changes. Brain 1943;66:163-203.
78. Danis R, Appen RE. Optic atrophy and the Wyburn-Mason syndrome. J Clin Neuro Ophthalmol 1984;4:91-5.
79. Lecuire J, Dechaume JP, Bret P. Bonnet-Dechaume-Blanc syndrome. In: Vinken PJ, Bruyn GW, editors. The phakomatoses, handbook of clinical neurology. Vol 14. Amsterdam: North Holland Publishing Company, 1972: 260-6.
80. Ferry A. Other phakomatoses. In: Ryan S, editor. Retina. 2nd ed. Vol 1. St Louis: C V Mosby Company, 1993:653-6.
81. Mansour AM, Walsh JB, Henking P. Arteriovenous anastomosis of retina. Ophthalmology 1987;94:35-40.